KINDSTAR GLOBAL

Kindstar Globalgene traded flat at HK$1.00 during the morning session, recovering from an intraday low of HK$0.980, with a daily range of about 2%. The stock was supported by the company's ongoing share buyback and cancellation activities, as evidenced by multiple recent HKEX filings, coupled with the FY26 H1 results released last night showing a 44.7% narrowing of net loss to RMB 18.1 million, while revenue grew 3.7% to RMB 473.6 million. The current price is 35.9% below the 52-week high of HK$1.56 but has reclaimed both the 20-day MA (HK$0.956) and 60-day MA (HK$0.965), though the year-to-date decline stands at 14.53%. However, the company remains loss-making with a P/E of -21.59x and a P/B of 0.35x, warranting caution on the sustainability of the turnaround.

Kindstar Global closed at HKD 0.995, flat from the previous close, after a session that saw prices dip to HKD 0.970 in the morning before recovering in the afternoon. Frequent share buybacks (e.g., at HKD 0.94-0.99 for cancellation) provided support, while the interim net loss narrowed 44.7% to RMB 18.1 million with revenue up 3.7% to RMB 473.6 million, driven by oncology testing. Despite the improvement, the net profit margin remained negative. The stock trades 41.5% below its 52-week high of HKD 1.71 and below both the MA20 (HKD 0.951) and MA60 (HKD 0.966), indicating a depressed valuation, though YTD it is down 14.5% with thin overall volume of 865,000 shares.

Kindstar Globalgene opened morning session at HKD 0.98, quickly dipped to HKD 0.93, then fluctuated near HKD 0.95, closing 2.1% lower at HKD 0.95 on volume of 418,000 shares and turnover of approximately HKD 410,000. The company's FY2026 H1 revenue rose 3.7% to HKD 473.6 million, while net loss narrowed sharply by 44.7% to HKD 18.1 million, driven by oncology testing growth. Despite the loss narrowing, the stock remains 44.2% below its 52-week high of HKD 1.72 and below the 60-day MA of HKD 0.966, indicating cautious sentiment. However, with a price-to-book ratio of just 0.33x and ongoing share buybacks (at HKD 0.95-0.99 range), the stock finds some support.

Kindstar Globalgene opened lower and staged a recovery in the morning session, driven by its FY26 H1 net loss narrowing 44.7% YoY to RMB 18.1 million with revenue up 3.7% to RMB 473.6 million, led by oncology testing growth, alongside sustained share buyback activities (nearly 30 HKEX disclosures) providing support; the stock rebounded from an intraday low of HKD 0.92 to HKD 0.96, carving a 4.7% intraday range, though it remains 44.19% below the 52-week high of HKD 1.72 and below the MA60 (HKD 0.967), with YTD decline of 17.95% and a PB of 0.33x, suggesting lingering concerns over the sustainability of earnings improvement.

Kindstar Globalgene opened lower and drifted down in the morning session, closing 1.1% lower at HKD 0.91, hitting a 52-week low of HKD 0.91 intraday, 47.4% below the 52-week high of HKD 1.73, with a year-to-date decline of 22.2%, and trading below both MA20 (0.941) and MA60 (0.967). The company's latest FY26 H1 results showed net loss narrowed 44.7% to RMB 18.1 million while revenue grew 3.7% to RMB 473.6 million, and Q4 2025 net profit improved 64.4% YoY to a loss of HKD 12.6 million, but the fundamental improvement has yet to reverse the stock's downtrend. The company has been actively repurchasing shares over the past 30 days, with multiple HKEX disclosures (e.g., at HKD 0.95-0.97), yet market reaction has been muted, with the stock rising 3% on one buyback announcement only to retreat over 3% later, indicating a tug-of-war between buyers and sellers. While the current price-to-book ratio of 0.31x may offer some valuation support, the stock remains under pressure.